Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
243 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Worldwide Prevalence of Hereditary Angioedema: A Systematic Review and Meta-Analysis.
Fisch SA, Rundle AG, Neugut AI, et al. · Int Arch Allergy Immunol · 2025Systematic Review, Meta-Analysis
- Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
Riedl MA, Tachdjian R, Lumry WR, et al. · N Engl J Med · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.
Giménez-Arnau AM, Szalewski R, Hide M, et al. · J Allergy Clin Immunol · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Phlebotonics for venous insufficiency.
Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, et al. · Cochrane Database Syst Rev · 2020Meta-Analysis, Research Support, Non-U.S. Gov't
- CRISPR-Based Therapy for Hereditary Angioedema.
Cohn DM, Gurugama P, Magerl M, et al. · N Engl J Med · 2025Clinical Trial, Phase II, Multicenter Study
- Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.
Riedl MA, Farkas H, Aygören-Pürsün E, et al. · N Engl J Med · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
Banerji A, Riedl MA, Bernstein JA, et al. · JAMA · 2018Clinical Trial, Phase III, Comparative Study
- Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
Banerji A, Bernstein JA, Johnston DT, et al. · Allergy · 2022Clinical Trial, Research Support, Non-U.S. Gov't
- Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis.
Riedl MA, Bernstein JA, Jacobs JS, et al. · J Allergy Clin Immunol Pract · 2025Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ, Reshef A, Li HH, et al. · Lancet · 2023Randomized Controlled Trial, Multicenter Study
- Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema.
Walsh S, Bartlett M, Salvo-Halloran EM, et al. · Drugs R D · 2025Network Meta-Analysis, Systematic Review
- CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.
Longhurst HJ, Lindsay K, Petersen RS, et al. · N Engl J Med · 2024Clinical Trial, Phase I
- Inhibition of Prekallikrein for Hereditary Angioedema.
Fijen LM, Riedl MA, Bordone L, et al. · N Engl J Med · 2022Clinical Trial, Phase II, Multicenter Study
- Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension.
Farkas H, Anderson J, Bouillet L, et al. · J Allergy Clin Immunol Pract · 2025Multicenter Study, Clinical Trial, Phase III
- Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to <12 years: APeX-P interim results.
Bernatoniene J, Bourgoin-Heck M, Cancian M, et al. · Ann Allergy Asthma Immunol · 2025Clinical Trial, Phase III, Multicenter Study
- Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
Reshef A, Hsu C, Katelaris CH, et al. · Allergy · 2025Clinical Trial, Phase III, Multicenter Study
- Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Zuraw B, Lumry WR, Johnston DT, et al. · J Allergy Clin Immunol · 2021Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of Donidalorsen in Hereditary Angioedema with C1 inhibitor deficiency: a systematic review and a meta analysis.
Raja A, Shuja MH, Raja S, et al. · Arch Dermatol Res · 2024Meta-Analysis, Systematic Review
- Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review.
Longhurst HJ, Cancian M, Grivcheva-Panovska V, et al. · Clin Rev Allergy Immunol · 2024Systematic Review
- Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, et al. · Lancet · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: A randomized-controlled trial.
Petersen RS, Fijen LM, Kelder JP, et al. · J Allergy Clin Immunol · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.
Cohn DM, Gurugama P, Longhurst HJ, et al. · N Engl J Med · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents.
Craig T, Tachdjian R, Bernstein JA, et al. · Ann Allergy Asthma Immunol · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Psychology and hereditary angioedema: A systematic review.
Savarese L, Mormile I, Bova M, et al. · Allergy Asthma Proc · 2021Systematic Review
- Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Craig TJ, Levy DS, Reshef A, et al. · Lancet Haematol · 2024Clinical Trial, Phase II, Randomized Controlled Trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.